Archana K Chandra, NP
Nurse Practitioner · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 2
- Since medical school
- 7 years
- Graduated 2019
Offices
2 locations · University of California San Francisco · 1,780 clinicians in this group
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Archana K Chandra’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$17,396
Medicare paid this office $17,396 for 118 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 70 | $8,929 | $108 |
| Return visit (30+ min) | 42 | $3,615 | $71 |
| Test for allergy using ingested items, initial 2 hours | 25 | $1,633 | $54 |
Who their Medicare patients are
118 Original Medicare patients in 2024. Average age 68 · Women 71% · Also on Medicaid 35% · Health risk score 2.15. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 53% · Depression 31% · Chronic kidney disease 26% · Diabetes 25% · Coronary heart disease 23% · Cancer 21% · COPD 20% · Atrial fibrillation 14% · Heart failure 13%.
The office billed $150,786, Medicare allowed $22,270 and paid $17,396; for 538 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 118 | 538 | 68 | 2.15 | $150,786 | $17,396 |
| 2023 | 156 | 537 | 68 | 2.08 | $179,499 | $22,506 |
| 2022 | 51 | 453 | 67 | 1.55 | $48,241 | $9,312 |
| 2021 | 41 | 882 | 72 | 1.17 | $32,138 | $6,652 |
| 2020 | 130 | 1,462 | 69 | 1.04 | $35,862 | $16,281 |
| 2019 | 118 | 1,461 | 69 | 1.15 | $36,485 | $15,124 |
| 2018 | 41 | 376 | 66 | 1.09 | $9,644 | $4,196 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 106 | $14,630 | $106 |
| Return visit (30+ min) | 33 | $2,597 | $70 |
| New patient visit (60+ min) | 18 | $2,188 | $122 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 15 | $139 | $9 |
2022: 1 service
| Long return visit (40+ min) | 21 | $2,529 | $110 |
2021: 2 services
| Test for allergy using allergenic extract | 16 | $2,080 | $3 |
| Short return visit (20+ min) | 15 | $656 | $41 |
2020: 5 services
| Short return visit (20+ min) | 110 | $6,665 | $52 |
| Test for allergy using allergenic extract | 14 | $2,993 | $3 |
| Test to measure expiratory airflow and volume | 59 | $1,827 | $26 |
| Return visit (30+ min) | 16 | $1,404 | $74 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 12 | $524 | $44 |
2019: 8 services
| Short return visit (20+ min) | 95 | $5,705 | $46 |
| Test for allergy using allergenic extract | 11 | $2,411 | $3 |
| Test to measure expiratory airflow and volume | 47 | $1,408 | $23 |
| Return visit (30+ min) | 11 | $909 | $76 |
| New patient visit (30+ min) | 14 | $676 | $48 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 11 | $385 | $35 |
| Inhalation treatment for airway obstruction or sputum production | 11 | $117 | $11 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 11 | $1 | None |
2018: 2 services
| Short return visit (20+ min) | 37 | $1,948 | $50 |
| Test to measure expiratory airflow and volume | 14 | $379 | $25 |
Medicaid work
$4,447 in 2022
Medicaid paid $4,447 for 81 billed services this clinician did in 2022, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| New patient visit (30+ min) | 27 | $2,298 |
| Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests | 34 | $2,007 |
| Professional services for allergen immunotherapy not including provision of allergenic extracts; 2 or more injections | 20 | $142 |
| 2022 | 81 | 3 | 21 | $4,447 |
| 2021 | 309 | 5 | 35 | $25,110 |
See the largest Medicaid services in earlier years
2021
| Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests | 167 | $12,046 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 55 | $5,611 |
| New patient visit (45+ min) | 37 | $4,050 |
| New patient visit (30+ min) | 38 | $2,837 |
| Short return visit (20+ min) | 12 | $566 |
Drugs they prescribed that Part D paid
$514,751
Pharmacies billed $514,751 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 726) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
437 generic and 289 brand-name prescriptions · $514,751 in drug cost · 16 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 59 | $222,759 | $3,776 |
| Dupixent | 17 | $59,960 | $3,527 |
| Trelegy Ellipta | 11 | $17,268 | $1,570 |
| Odactra | 19 | $9,891 | $521 |
| Spiriva Handihaler | 12 | $8,971 | $748 |
See all 14 drugs
| Dupixent | 59 | $222,759 | $3,776 |
| Dupixent | 17 | $59,960 | $3,527 |
| Trelegy Ellipta | 11 | $17,268 | $1,570 |
| Odactra | 19 | $9,891 | $521 |
| Spiriva Handihaler | 12 | $8,971 | $748 |
| Symbicort | 27 | $7,830 | $290 |
| Epinephrine | 29 | $5,825 | $201 |
| Azelastine | 104 | $4,858 | $47 |
| Azelastine-Fluticasone | 16 | $3,179 | $199 |
| Ipratropium | 101 | $3,020 | $30 |
| Arnuity Ellipta | 13 | $2,583 | $199 |
| Albuterol Sulfate Hfa | 18 | $871 | $48 |
| Fluticasone Propionate | 41 | $754 | $18 |
| Montelukast | 64 | $743 | $12 |
Year by year
| 2024 | 726 | 183 | 0% (0) | 40% | $514,751 |
| 2023 | 565 | 125 | 0% (0) | None | $352,417 |
| 2022 | 200 | 85 | 0% (0) | None | $97,354 |
| 2021 | 375 | 126 | 0% (0) | 33% | $58,778 |
| 2020 | 944 | 311 | None | 33% | $120,880 |
| 2019 | 751 | 225 | None | 36% | $98,752 |
| 2018 | 1,050 | 210 | 0% (0) | 33% | $131,620 |
| 2017 | 842 | 180 | 0% (0) | 30% | $76,946 |
| 2016 | 841 | 174 | 0% (0) | 38% | $90,403 |
| 2015 | 322 | 108 | 0% (0) | 47% | $34,127 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Dupixent | 26 | $99,469 | $3,826 |
| Nucala | 12 | $63,279 | $5,273 |
| Dupixent | 13 | $51,041 | $3,926 |
| Symbicort | 20 | $12,965 | $648 |
| Azelastine | 110 | $6,142 | $56 |
| Oralair | 12 | $5,908 | $492 |
| Odactra | 12 | $3,985 | $332 |
| Azelastine-Fluticasone | 22 | $3,914 | $178 |
| Qvar Redihaler | 12 | $3,237 | $270 |
| Ipratropium | 72 | $3,111 | $43 |
| Epinephrine | 11 | $2,564 | $233 |
| Montelukast | 54 | $547 | $10 |
| Fluticasone Propionate | 27 | $457 | $17 |
2022: 4 drugs
| Azelastine | 44 | $3,090 | $70 |
| Epinephrine | 11 | $2,476 | $225 |
| Ipratropium | 12 | $937 | $78 |
| Montelukast | 22 | $591 | $27 |
2021: 10 drugs
| Breo Ellipta | 25 | $10,666 | $427 |
| Spiriva Respimat | 11 | $9,069 | $824 |
| Advair Hfa | 16 | $6,794 | $425 |
| Trelegy Ellipta | 11 | $5,748 | $523 |
| Azelastine | 60 | $3,057 | $51 |
| Ipratropium | 22 | $1,284 | $58 |
| Mometasone Furoate | 11 | $1,192 | $108 |
| Montelukast | 65 | $783 | $12 |
| Albuterol Sulfate Hfa | 18 | $739 | $41 |
| Fluticasone Propionate | 42 | $699 | $17 |
2020: 16 drugs
| Breo Ellipta | 39 | $17,807 | $457 |
| Spiriva Respimat | 22 | $13,858 | $630 |
| Advair Hfa | 25 | $12,940 | $518 |
| Symbicort | 23 | $12,697 | $552 |
| Incruse Ellipta | 20 | $8,580 | $429 |
| Flovent Hfa | 25 | $6,946 | $278 |
| Azelastine | 125 | $6,710 | $54 |
| Fluticasone Propionate | 164 | $3,112 | $19 |
| Albuterol Sulfate Hfa | 61 | $2,537 | $42 |
| Ventolin Hfa | 34 | $1,995 | $59 |
| Ipratropium | 32 | $1,472 | $46 |
| Montelukast | 111 | $1,375 | $12 |
| Levocetirizine Dihydrochloride | 16 | $426 | $27 |
| Famotidine | 12 | $171 | $14 |
| Prednisone | 30 | $82 | $3 |
| Azithromycin | 14 | $80 | $6 |
2019: 13 drugs
| Breo Ellipta | 61 | $28,012 | $459 |
| Spiriva Respimat | 31 | $15,341 | $495 |
| Symbicort | 29 | $11,684 | $403 |
| Incruse Ellipta | 24 | $10,298 | $429 |
| Azelastine | 92 | $4,272 | $46 |
| Arnuity Ellipta | 19 | $4,044 | $213 |
| Fluticasone Propionate | 146 | $2,231 | $15 |
| Ventolin Hfa | 26 | $1,481 | $57 |
| Montelukast | 111 | $1,357 | $12 |
| Ipratropium | 38 | $1,349 | $36 |
| Albuterol Sulfate Hfa | 12 | $571 | $48 |
| Ranitidine | 18 | $151 | $8 |
| Omeprazole | 13 | $132 | $10 |
2018: 18 drugs
| Breo Ellipta | 117 | $46,153 | $394 |
| Spiriva Respimat | 53 | $23,806 | $449 |
| Advair Diskus | 19 | $9,775 | $514 |
| Symbicort | 27 | $9,632 | $357 |
| Incruse Ellipta | 19 | $6,304 | $332 |
| Azelastine | 127 | $5,948 | $47 |
| Arnuity Ellipta | 22 | $4,087 | $186 |
| Olopatadine | 21 | $2,651 | $126 |
| Ipratropium | 73 | $2,426 | $33 |
| Fluticasone Propionate | 198 | $2,301 | $12 |
| Ventolin Hfa | 39 | $2,150 | $55 |
| Mometasone Furoate | 11 | $1,594 | $145 |
| Montelukast | 143 | $1,368 | $10 |
| Proair Hfa | 14 | $846 | $60 |
| Ranitidine | 60 | $362 | $6 |
| Azithromycin | 12 | $117 | $10 |
| Omeprazole | 14 | $62 | $4 |
| Prednisone | 15 | $44 | $3 |
2017: 14 drugs
| Breo Ellipta | 64 | $21,603 | $338 |
| Symbicort | 25 | $9,370 | $375 |
| Spiriva Respimat | 20 | $7,443 | $372 |
| Advair Diskus | 19 | $7,290 | $384 |
| Azelastine | 121 | $5,415 | $45 |
| Arnuity Ellipta | 16 | $2,672 | $167 |
| Fluticasone Propionate | 204 | $2,472 | $12 |
| Ipratropium | 43 | $1,645 | $38 |
| Proair Hfa | 19 | $1,339 | $70 |
| Montelukast | 117 | $1,301 | $11 |
| Ventolin Hfa | 24 | $1,274 | $53 |
| Ranitidine | 42 | $215 | $5 |
| Omeprazole | 11 | $54 | $5 |
| Prednisone | 11 | $35 | $3 |
2016: 15 drugs
| Advair Diskus | 50 | $19,724 | $394 |
| Spiriva | 36 | $12,277 | $341 |
| Symbicort | 22 | $6,946 | $316 |
| Breo Ellipta | 22 | $6,671 | $303 |
| Azelastine | 101 | $4,533 | $45 |
| Qvar | 22 | $4,192 | $191 |
| Advair Hfa | 12 | $4,079 | $340 |
| Flovent Hfa | 15 | $3,338 | $223 |
| Fluticasone Propionate | 207 | $2,177 | $11 |
| Proair Hfa | 31 | $1,681 | $54 |
| Ventolin Hfa | 25 | $1,300 | $52 |
| Montelukast | 81 | $944 | $12 |
| Ipratropium | 32 | $827 | $26 |
| Ranitidine | 36 | $272 | $8 |
| Omeprazole | 11 | $81 | $7 |
2015: 8 drugs
| Advair Hfa | 14 | $5,224 | $373 |
| Advair Diskus | 13 | $4,778 | $368 |
| Dulera | 11 | $3,870 | $352 |
| Proair Hfa | 32 | $1,599 | $50 |
| Azelastine | 25 | $1,303 | $52 |
| Fluticasone Propionate | 67 | $836 | $12 |
| Montelukast | 36 | $463 | $13 |
| Triamcinolone Acetonide | 12 | $209 | $17 |
Money from drug and device companies
$64 in 2022
| 2022 | 1 | 2 | None | $64 |
| 2021 | 1 | 1 | None | $22 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Takeda Pharmaceuticals U.S.A. | Hyqvia | $64 | 2 payments
|
See all 2 published payments
| Takeda Pharmaceuticals U.S.A. | Meals · 2022-08-03 | Hyqvia | $33 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2022-04-26 | Takhzyro | $31 |
See earlier years (2021)
2021: $22
| Boehringer Ingelheim Pharmaceuticals | Spiriva Respimat | $22 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1518358142
- Licence
- CA NP95002003
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA GR0043790
- Taxonomy
- Nurse practitioner (363L00000X)
- Mailing address
- 400 Parnassus Ave, San Francisco, CA, 94143
- NPI first listed
- 2015-02-18
- NPI last updated
- 2022-02-27
- NPI record certified
- 2022-02-27
This is when the NPI record was last certified, not a medical board exam.